Cromos Pharma, where the patients are

Clinical Intelligence

Enlivex Therapeutics’ positive results from phase I/II bone marrow transplant trial

Tuesday, November 5, 2013 09:00 AM

Enlivex Therapeutics has published a scientific paper in the American Society for Blood and Marrow Transplantation titled “Biology of Blood and Marrow Transplantation.”

More... »

CRF Health eCOA webinar series

The CenterWatch Monthly, November 2013

Friday, November 1, 2013 09:41 AM

AMCs show renewed interest in industry research

More... »

VisionGate Cell-CT 3D imaging platform detects lung cancer

Tuesday, October 29, 2013 11:04 AM

VisionGate, a developer of a non-invasive test for the early detection of lung cancer, has reported clinical data showing that its automated 3D cell imaging platform, the Cell-CT, can detect lung cancer in sputum samples with high sensitivity and specificity.

More... »

AB-Biotics acquires patent for predicting antipsychotic-induced extrapyramidal symptoms

Tuesday, October 29, 2013 10:00 AM

The Spanish biotech company AB-Biotics has acquired the rights to a patent which predicts the high or low risk of a patient treated with antipsychotic drugs developing extrapyramidal symptoms. Side effects induced by antipsychotic drugs affect patient movement and include muscle rigidity, parkinsonism, akinesia (inability to initiate movement) and akathisia (inability to remain motionless).

More... »

Palatin Technologies reports successful completion of device bioequivalence trial

Tuesday, October 29, 2013 09:00 AM

Palatin Technologies has announced the successful completion of a clinical trial designed to demonstrate equivalence of subcutaneously administered bremelanotide via autoinjector compared to pre-filled syringe administration. Bioequivalence was achieved in this clinical trial. Palatin used pre-filled syringes in its phase II clinical trials, but will use the single-dose disposable autoinjector in its planned phase III clinical trials and for commercialization.

More... »

FDA approves Actelion's Opsumit for pulmonary arterial hypertension

Monday, October 21, 2013 12:53 PM

The FDA has approved Opsumit (macitentan), a new drug to treat adults with pulmonary arterial hypertension (PAH), a chronic, progressive and debilitating disease that can lead to death or the need for lung transplantation.

More... »

Evotec receives $5.4 million milestone payment from Boehringer Ingelheim

Monday, October 21, 2013 11:52 AM

Evotec’s research alliance with Boehringer Ingelheim has reached a milestone in September triggering revenues of $5.4 million to Evotec. The milestone was for the transition of an oncology molecule into pre-clinical development.

More... »

New brain technology for ALS patients will launch clinical trials in Philadelphia

Monday, October 21, 2013 08:00 AM

A new technology that will enable patients suffering from ALS—commonly known as Lou Gehrig's disease—to communicate via brain monitor, will hold its first clinical trials in Philadelphia. Congressman Chaka Fattah (PA-02) was on hand for the announcement, made Tuesday at the BrainTech Israel conference in Tel Aviv.

More... »

Isis earns $10 million milestone payment from Biogen Idec

Thursday, October 17, 2013 10:31 AM

Isis Pharmaceuticals has earned a $10 million milestone payment from Biogen Idec related to the selection and advancement of ISIS-DMPKRx to treat myotonic dystrophy type I (DM1).

More... »

Novella Clinical selected by Scioderm to manage rare disease study

Thursday, October 17, 2013 09:01 AM

CRO Novella Clinical, a Quintiles company, has been selected by Scioderm, is a privately held, clinical-stage pharmaceutical company, to manage a phase IIb trial for the treatment of Epidermolysis Bullosa (EB), a rare genetic connective tissue condition. The trial will evaluate Scioderm’s investigational topical product, SD-101, for the treatment of skin blistering and erosions associated with this disease, including facilitation of healing of skin lesions and reduction of the incidence and/or severity of new lesions.

More... »

CenterWatch Drugs in Clinical Trials



Browse by:


April 14

Proposal calls for back-to-back trials to measure efficacy and effectiveness prior to FDA approval

Study: Minority populations under-represented in cancer trials, but have higher rates of incidence

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly


Make way for mobile health in clinical trials
Despite patient retention, data quality benefits, regulatory hurdles persist

Global clinical trial laboratories decentralize
Regional labs reducing complexity, delivering cost and time savings

Already a subscriber?
Log in to your digital subscription.

Purchase the April issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly


Strategic alliances hit bumps in the road
Mixed relationship performance driving new approaches

Tapping community hospitals for clinical trial volunteers
New study finds high potential but infrastructure, resources are lacking

Already a subscriber?
Log in to your digital subscription.

Purchase the March issue.

Subscribe to
The CenterWatch Monthly.


Featured Jobs